UNSPSC 51141587: Acetazolamide sodium

This classification denotes a diuretic and carbonic anhydrase inhibitor with the molecular formula C4H5N4O3S2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 429ZT169UH, chemically known as 1,3,4-thiadiazole-2-sulfonamide, 5-acetamido- but more generally known as acetazolamide sodium, which bears US NIH Compound Identifier 1986. The base compound, Acetazolamide, also comes in forms adipate ethyl ester, methyl, and tri-methyl.

UNSPSC 51141587 Acetazolamide sodium is a Commodity code that nominally designates a specific pharmaceutical compound, but recent state and local opportunities show little direct procurement activity under this code itself. Instead, the opportunities tagged to this code reflect broader pharmaceutical and health-product procurement — naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing, and direct-to-manufacturer prescription programs. State and local buyers under this family include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. The actual work being solicited ranges from one-time or recurring purchases of specific branded or generic drugs (often through established wholesaler networks) to exploratory market-research activities that precede formal pharmaceutical contracting vehicles.

Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, closing July 26, 2023 (note: the due date reflects a data inconsistency in the source). The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026 and contract performance spanning multiple state and local facilities including Oregon; MMCAP evaluates proposals on fixed pricing, administrative compliance, EDI capability, and price competitiveness (75 percent weight). The Texas Health and Human Services Commission issued an RFI in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs, signaling early-stage procurement intent rather than a formal solicitation. Geographic activity centers on Florida, Minnesota, Texas, and the broader multistate cooperative-purchasing footprint. Vendors should expect compliance requirements including cGMP and Drug Supply Chain Security Act certification, E-Verify eligibility confirmation, and substantial insurance coverage ($2,000,000 to $5,000,000 depending on coverage type); cooperative purchasing contracts typically include administrative fees and performance-penalty structures.